Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment.

Kim KD, Bae S, Capece T, Nedelkovska H, de Rubio RG, Smrcka AV, Jun CD, Jung W, Park B, Kim TI, Kim M.

Nat Commun. 2017 May 15;8:15365. doi: 10.1038/ncomms15365.

2.

A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.

Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai NY, Weiner DB.

Mol Ther. 2017 Apr 5;25(4):976-988. doi: 10.1016/j.ymthe.2017.01.022. Epub 2017 Feb 22.

PMID:
28237837
3.

Overview on poly(ADP-ribose) immuno-biomedicine and future prospects.

Kanai Y.

Proc Jpn Acad Ser B Phys Biol Sci. 2016;92(7):222-36. doi: 10.2183/pjab.92.222. Review.

4.

An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects.

Cho HI, Jung SH, Sohn HJ, Celis E, Kim TG.

Oncoimmunology. 2015 May 26;4(11):e1043504. eCollection 2015 Nov.

5.

Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides.

Adegoke AO, Grant MD.

Front Immunol. 2015 Jul 23;6:377. doi: 10.3389/fimmu.2015.00377. eCollection 2015. Review.

6.

Evolution of animal models in cancer vaccine development.

Wei WZ, Jones RF, Juhasz C, Gibson H, Veenstra J.

Vaccine. 2015 Dec 16;33(51):7401-7407. doi: 10.1016/j.vaccine.2015.07.075. Epub 2015 Aug 1. Review.

7.

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM.

BMC Vet Res. 2015 Jun 11;11:132. doi: 10.1186/s12917-015-0422-9.

8.

DNA vaccines, electroporation and their applications in cancer treatment.

Lee SH, Danishmalik SN, Sin JI.

Hum Vaccin Immunother. 2015;11(8):1889-900. doi: 10.1080/21645515.2015.1035502. Review.

9.

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM.

BMC Vet Res. 2015 May 14;11:107. doi: 10.1186/s12917-015-0414-9.

10.

Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.

Aurisicchio L, Roscilli G, Marra E, Luberto L, Mancini R, La Monica N, Ciliberto G.

Hum Gene Ther. 2015 Jun;26(6):386-98. doi: 10.1089/hum.2014.141.

11.

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.

Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD.

J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013.

12.

Enhanced responses to tumor immunization following total body irradiation are time-dependent.

Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, Houghton AN, Perales MA.

PLoS One. 2013 Dec 12;8(12):e82496. doi: 10.1371/journal.pone.0082496. eCollection 2013.

13.

Targeting c-MYC with T-cells.

Helm F, Kammertoens T, Lehmann FM, Wilke A, Bruns H, Mautner J, Bornkamm GW, Gerbitz A.

PLoS One. 2013 Oct 10;8(10):e77375. doi: 10.1371/journal.pone.0077375. eCollection 2013.

14.

Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.

Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R.

Mol Ther. 2013 Aug;21(8):1507-16. doi: 10.1038/mt.2013.116. Epub 2013 Jun 11.

15.

Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice.

Kalli F, Machiorlatti R, Battaglia F, Parodi A, Conteduca G, Ferrera F, Proietti M, Tardito S, Sanguineti M, Millo E, Fenoglio D, De Palma R, Inghirami G, Filaci G.

J Transl Med. 2013 May 12;11:120. doi: 10.1186/1479-5876-11-120.

16.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H.

Cancer Cell. 2013 Apr 15;23(4):516-26. doi: 10.1016/j.ccr.2013.03.018.

17.
18.

Cross-reactivity of T cells and its role in the immune system.

Petrova G, Ferrante A, Gorski J.

Crit Rev Immunol. 2012;32(4):349-72. Review.

19.

A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy.

Cho HI, Reyes-Vargas E, Delgado JC, Celis E.

Cancer Res. 2012 Apr 15;72(8):1986-95. doi: 10.1158/0008-5472.CAN-11-3246. Epub 2012 Feb 24.

20.

New perspectives on the role of vitiligo in immune responses to melanoma.

Byrne KT, Turk MJ.

Oncotarget. 2011 Sep;2(9):684-94. Review.

Supplemental Content

Support Center